Feeds:
Posts
Comments

Posts Tagged ‘MicroRNA’

Stanford Study Finds miRNA-320a a Broad Regulator of Glycolysis, Potential Drug Target

 Reporter: Aviva Lev-Ari, PhD, RN

A study by Stanford researchers has found that microRNA-320a appears to regulate glycolysis in response to oxidative stress in several biological systems, including lung cancer and wasting of disused muscle.

The Stanford team was initially interested in better understanding the wasting of diaphragm muscles due to mechanical ventilation, but expanded its study to look at lung cancer and an experimental in vitro model of oxidative stress, as well as the similarity of pathogenic glycolytic pathways across these biological systems.

The group profiled miRNA and protein expression in samples from human diaphragm muscles under mechanical ventilation to identify miRNAs associated with the glycolytic rate-limiting enzyme phosphofructokinase, or PFKm, without which glycolysis is reduced.

The group initially identified 28 miRNAs that were significantly downregulated and three that were upregulated in the ventilated human diaphragm samples. Using predictive software, the group pinpointed miR-320a as being potentially involved in the regulation PFKm.

To validate miR-320a, the researchers looked at all three experimental systems — samples of diaphragm tissue, lung cancer, and an in vitro cell model under oxidative stress. In all three, miR-320a was down-regulated in the samples versus the control.

The group also confirmed that miR-320a influences PFKm in each system, and further demonstrated that miR-320a knockdown increased lactate levels in vitro; and thathigher miR-320a levels reduced lactate levels in in vivo mouse experiments.

The group wrote that the study shows for the first time that glycolytic activity “is increased in diaphragm tissue that is noncontractile as a result of full mechanical ventilator support.” The results also confirmed that glycolysis up-regulation, or the Warburg effect, is present in lung adenocarcinoma, and that both otherwise divergent disorders are in fact linked by the influence of miR-320a.

The finding has implications for cancer treatment, as well as more effective treatment for dysfunctional diaphragm muscles following breathing support using a ventilator, according to the team, which published the study online in the FASEB Journal earlier this month.

Glycolysis is the process of converting sugar into energy, and is implicated in the growth of some cancers through a process called the Warburg effect. To the Stanford team, the Warburg effect seen in lung adenocarcinoma “appears to closely mimic” that of dysfunctional human diaphragm tissue after mechanical ventilation therapy, a condition called ventilator-induced diaphragm dysfunction, or VIDD.

The Stanford researchers claim that their study shows that these very divergent biological systems share the same glycolysis regulatory apparatus involving miR-320a, which the authors believe they are the first to identify.

Additionally, “miR-320 regulation of glycolysis may represent a general mechanism underlying other clinical diseases that are associated with changes in energy supply,” the researchers wrote, such as cardiac ischemia, to insulin resistance.

In cancer specifically, down-regulation of miR-320a has been previously reported in a number of malignancies, the group reported. Coupled with the fact that the Warburg effect is thought to be important in many cancers, and the results of the group’s study in adenocarcinoma, this suggests that miR-320a “may be directly related” to the development of cancer, and that the associated glycolysis may be a potential drug target.

FASEB J. 2012 Jul 5. [Epub ahead of print]

Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems.

Tang HLee MSharpe OSalamone LNoonan EJHoang CDLevine SRobinson WHShrager JB.

Source

*Division of Thoracic Surgery, Department of Cardiothoracic Surgery.

Abstract

Glycolysis is the initial step of glucose catabolism and is up-regulated in cancer cells (the Warburg Effect). Such shifts toward a glycolytic phenotype have not been explored widely in other biological systems, and the molecular mechanisms underlying the shifts remain unknown. With proteomics, we observed increased glycolysis in disused human diaphragm muscle. In disused muscle, lung cancer, and H(2)O(2)-treated myotubes, we show up-regulation of the rate-limiting glycolytic enzyme muscle-type phosphofructokinase (PFKm, >2 fold, P<0.05) and accumulation of lactate (>150%, P<0.05). Using microRNA profiling, we identify miR-320a as a regulator of PFKm expression. Reduced miR-320a levels (to ∼50% of control, P<0.05) are associated with the increased PFKm in each of these diverse systems. Manipulation of miR-320a levels both in vitro and in vivo alters PFKm and lactate levels in the expected directions. Further, miR-320a appears to regulate oxidative stress-induced PFKm expression, and reduced miR-320a allows greater induction of glycolysis in response to H(2)O(2) treatment. We show that this microRNA-mediated regulation occurs through PFKm’s 3′ untranslated region and that Ets proteins are involved in the regulation of PFKm via miR-320a. These findings suggest that oxidative stress-responsive microRNA-320a may regulate glycolysis broadly within nature.-Tang, H., Lee, M., Sharpe, O., Salamone, L., Noonan, E. J., Hoang, C. D., Levine, S., Robinson, W. H., Shrager, J. B. Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems.

Read Full Post »

Reporter: Prabodh Kandala, PhD.

A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes(CN-AML).

The study by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) found that when microRNA-3151 (miR-3151) is overexpressed in CN-AML, the disease responds poorly to treatment and patients experience shorter remissions and survival periods. This effect is independent of other gene mutations that may be present in the cells.

Additionally, miR-3151 is encoded within a gene called BAALC, which itself is an independent marker of poor survival when overexpressed in CN-AML.

The findings, published online in the journal Blood (and as a Plenary paper which represents the top 1 to 5 percent of papers published in the print edition of Blood), provide new insights into the nature of AML and might in the future help determine the best therapy for individual patients and further personalize AML therapy.

“Patients with high levels of both miR-3151 and BAALC had the poorest outcome compared with those showing high expression of either miR-3151 or BAALC alone, or those expressing low levels of both,” says principal investigator Dr. Clara D. Bloomfield, a Distinguished University Professor at Ohio State and cancer scholar and senior advisor to the OSUCCC — James. “This suggests that miR-3151 and BAALC may act through different mechanisms to enhance poor outcome of CN-AML patients.”

The study involved 179 patients aged 60 years or older with CN-AML who were treated on Cancer and Leukemia Group B (CALGB) clinical trials.

MicroRNAs are small molecules that cells use to help regulate the kinds and amount of proteins they make. About one-third of human microRNAs are encoded within host genes. Specifically, they are located in the portions of genes called introns, short stretches of DNA that are not used when genetic information is translated to make a protein.

“Very little is known about the regulation of microRNAs located within introns, and especially about their possible interactions with their host genes,” says first author Dr. Ann-Kathrin Eisfeld, a post-doctoral researcher who works in the laboratory of study co-author Dr. Albert de la Chapelle and Bloomfield.

“This is the first description of interplay of an oncogene and its intronic, and possibly oncogenic, microRNA,” Eisfeld says. “It may be the first of other important intronic microRNAs in leukemia and perhaps other malignancies.”

Funding from the National Cancer Institute, the Coleman Leukemia Research Foundation, the Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation, the Pelotonia Fellowship Program and the Conquer Cancer Foundation supported this research.

Abstract:

High BAALC expression levels associate with poor outcome in cytogenetically normal AML (CN-AML) patients. Recently, microRNA miR-3151 was discovered in intron 1 of BAALC. To evaluate the prognostic significance of miR-3151expression levels and to gain insight into the biologic and prognostic interplay between miR-3151 and its host, miR-3151 and BAALC expression were measured in pretreatment blood of 179 CN-AML patients. Gene- (GEP) and microRNA-expression (MEP) profiling was performed using microarrays. HighmiR-3151 expression associated with shorter disease-free and overall survival, while high BAALC expression predicted failure of complete remission and shorter overall survival. Patients exhibiting high expression of both miR-3151and BAALC had worse outcome than patients expressing low levels of either gene or both genes. In GEP high miR-3151 expressers showed downregulation of genes involved in transcriptional regulation, post-translational modification and cancer pathways. Two genes, FBXL20 and USP40, were validated as directmiR-3151 targets. In conclusion, high expression of miR-3151 is an independent prognosticator for poor outcome in CN-AML and impacts on different outcome endpoints than its host gene BAALC. The combination of both markers identified a patient subset with the poorest outcome. The described interplay of an intronic miR and its host may have important biologic implications.

http://bloodjournal.hematologylibrary.org/content/early/2012/04/23/blood-2012-02-408492

http://www.sciencedaily.com/releases/2012/05/120514134307.htm

Read Full Post »

« Newer Posts